vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Lovesac Co (LOVE). Click either name above to swap in a different company.
Lovesac Co is the larger business by last-quarter revenue ($150.2M vs $139.2M, roughly 1.1× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -7.0%, a 42.5% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 0.2%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-10.2M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -22.6%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
The Lovesac Company is an American furniture retailer, specializing in a patented modular furniture system called Sactionals. Sactionals consist of two combinable pieces, “Seats” and “Sides,” as well as custom-fit covers and associated accessories. Lovesac also sells Sacs, a bag seat filled with a proprietary foam mixture.
ADMA vs LOVE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $150.2M |
| Net Profit | $49.4M | $-10.6M |
| Gross Margin | 63.8% | 56.1% |
| Operating Margin | 45.1% | -10.5% |
| Net Margin | 35.5% | -7.0% |
| Revenue YoY | 18.4% | 0.2% |
| Net Profit YoY | -55.9% | -114.0% |
| EPS (diluted) | $0.20 | $-0.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $150.2M | ||
| Q3 25 | $134.2M | $160.5M | ||
| Q2 25 | $122.0M | $138.4M | ||
| Q1 25 | $114.8M | $241.5M | ||
| Q4 24 | $117.5M | $149.9M | ||
| Q3 24 | $119.8M | $156.6M | ||
| Q2 24 | $107.2M | $132.6M | ||
| Q1 24 | $81.9M | $250.5M |
| Q4 25 | $49.4M | $-10.6M | ||
| Q3 25 | $36.4M | $-6.7M | ||
| Q2 25 | $34.2M | $-10.8M | ||
| Q1 25 | $26.9M | $35.3M | ||
| Q4 24 | $111.9M | $-4.9M | ||
| Q3 24 | $35.9M | $-5.9M | ||
| Q2 24 | $32.1M | $-13.0M | ||
| Q1 24 | $17.8M | $31.0M |
| Q4 25 | 63.8% | 56.1% | ||
| Q3 25 | 56.3% | 56.4% | ||
| Q2 25 | 55.1% | 53.7% | ||
| Q1 25 | 53.2% | 60.4% | ||
| Q4 24 | 53.9% | 58.5% | ||
| Q3 24 | 49.8% | 59.0% | ||
| Q2 24 | 53.6% | 54.3% | ||
| Q1 24 | 47.8% | 59.7% |
| Q4 25 | 45.1% | -10.5% | ||
| Q3 25 | 38.0% | -5.5% | ||
| Q2 25 | 35.1% | -10.8% | ||
| Q1 25 | 30.4% | 19.7% | ||
| Q4 24 | 32.6% | -5.2% | ||
| Q3 24 | 33.1% | -5.3% | ||
| Q2 24 | 36.6% | -13.5% | ||
| Q1 24 | 26.7% | 16.1% |
| Q4 25 | 35.5% | -7.0% | ||
| Q3 25 | 27.1% | -4.1% | ||
| Q2 25 | 28.1% | -7.8% | ||
| Q1 25 | 23.4% | 14.6% | ||
| Q4 24 | 95.2% | -3.3% | ||
| Q3 24 | 30.0% | -3.7% | ||
| Q2 24 | 29.9% | -9.8% | ||
| Q1 24 | 21.7% | 12.4% |
| Q4 25 | $0.20 | $-0.72 | ||
| Q3 25 | $0.15 | $-0.45 | ||
| Q2 25 | $0.14 | $-0.73 | ||
| Q1 25 | $0.11 | $2.22 | ||
| Q4 24 | $0.45 | $-0.32 | ||
| Q3 24 | $0.15 | $-0.38 | ||
| Q2 24 | $0.13 | $-0.83 | ||
| Q1 24 | $0.08 | $1.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $23.7M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $189.3M |
| Total Assets | $624.2M | $495.5M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $23.7M | ||
| Q3 25 | $61.4M | $34.2M | ||
| Q2 25 | $90.3M | $26.9M | ||
| Q1 25 | $71.6M | $83.7M | ||
| Q4 24 | $103.1M | $61.7M | ||
| Q3 24 | $86.7M | $72.1M | ||
| Q2 24 | $88.2M | $72.4M | ||
| Q1 24 | $45.3M | $87.0M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $189.3M | ||
| Q3 25 | $431.2M | $197.5M | ||
| Q2 25 | $398.3M | $201.2M | ||
| Q1 25 | $373.4M | $216.4M | ||
| Q4 24 | $349.0M | $196.5M | ||
| Q3 24 | $231.9M | $202.1M | ||
| Q2 24 | $188.3M | $205.3M | ||
| Q1 24 | $153.7M | $217.5M |
| Q4 25 | $624.2M | $495.5M | ||
| Q3 25 | $568.7M | $493.7M | ||
| Q2 25 | $558.4M | $483.7M | ||
| Q1 25 | $510.6M | $532.3M | ||
| Q4 24 | $488.7M | $499.7M | ||
| Q3 24 | $390.6M | $481.1M | ||
| Q2 24 | $376.4M | $477.2M | ||
| Q1 24 | $350.9M | $482.2M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-4.9M |
| Free Cash FlowOCF − Capex | $34.6M | $-10.2M |
| FCF MarginFCF / Revenue | 24.8% | -6.8% |
| Capex IntensityCapex / Revenue | 0.8% | 3.5% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-4.9M | ||
| Q3 25 | $13.3M | $12.2M | ||
| Q2 25 | $21.1M | $-41.4M | ||
| Q1 25 | $-19.7M | $44.0M | ||
| Q4 24 | $50.2M | $-4.2M | ||
| Q3 24 | $25.0M | $6.2M | ||
| Q2 24 | $45.6M | $-7.0M | ||
| Q1 24 | $-2.2M | $56.3M |
| Q4 25 | $34.6M | $-10.2M | ||
| Q3 25 | $-1.1M | $7.8M | ||
| Q2 25 | $18.7M | $-50.0M | ||
| Q1 25 | $-24.4M | $38.7M | ||
| Q4 24 | $47.5M | $-6.6M | ||
| Q3 24 | $24.0M | $119.0K | ||
| Q2 24 | $43.6M | $-14.3M | ||
| Q1 24 | $-4.6M | $49.5M |
| Q4 25 | 24.8% | -6.8% | ||
| Q3 25 | -0.8% | 4.9% | ||
| Q2 25 | 15.3% | -36.1% | ||
| Q1 25 | -21.2% | 16.0% | ||
| Q4 24 | 40.4% | -4.4% | ||
| Q3 24 | 20.0% | 0.1% | ||
| Q2 24 | 40.7% | -10.8% | ||
| Q1 24 | -5.6% | 19.8% |
| Q4 25 | 0.8% | 3.5% | ||
| Q3 25 | 10.7% | 2.7% | ||
| Q2 25 | 2.0% | 6.2% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 2.3% | 1.6% | ||
| Q3 24 | 0.9% | 3.9% | ||
| Q2 24 | 1.9% | 5.5% | ||
| Q1 24 | 2.9% | 2.7% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | 1.25× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | 1.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
LOVE
| Showrooms | $102.7M | 68% |
| Internet | $37.3M | 25% |
| Other | $10.2M | 7% |
